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Background: Lung cancer, especially non-small cell lung cancer, is a leading cause of malignant tumor death
worldwide. Understanding the mechanisms employed by the main regulators, such as microRNAs (miRNAs) and
transcription factors (TFs), still remains elusive. The patterns of their cooperation and biological functions in the
synergistic regulatory network have rarely been studied.
Results: Here, we describe the first miRNA-TF synergistic regulation network in human lung cancer. We identified
important regulators (MYC, NFKB1, miR-590, and miR-570) and significant miRNA-TF synergistic regulatory motifs by
random simulations. The two most significant motifs were the co-regulation of miRNAs and TFs, and TF-mediated
cascade regulation. We also developed an algorithm to uncover the biological functions of the human lung cancer
miRNA-TF synergistic regulatory network (regulation of apoptosis, cellular protein metabolic process, and cell cycle),
and the specific functions of each miRNA-TF synergistic subnetwork. We found that the miR-17 family exerted
important effects in the regulation of non-small cell lung cancer, such as in proliferation and cell cycle regulation
by targeting the retinoblastoma protein (RB1) and forming a feed forward loop with the E2F1 TF. We proposed a
model for the miR-17 family, E2F1, and RB1 to demonstrate their potential roles in the occurrence and development
of non-small cell lung cancer.
Conclusions: This work will provide a framework for constructing miRNA-TF synergistic regulatory networks,
function analysis in diseases, and identification of the main regulators and regulatory motifs, which will be useful
for understanding the putative regulatory motifs involving miRNAs and TFs, and for predicting new targets for
cancer studies.
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Lung cancer, predominantly non-small cell lung cancer
(NSCLC), is a common cause of malignant tumor death
worldwide [1]. Since the end of the 20th century, lung
cancer has become the leading cause of malignant tumor* Correspondence: xuyan@ems.hrbmu.edu.cn
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reproduction in any medium, provided the ordeath, with morbidity and mortality gradually increasing
over the past 50 years. Active and passive tobacco smoking
is the best-known risk factor for lung cancer development.
Recent advances in genomics, epigenomics, transcripto-
mics, and molecular pathology, as well as in the sequencing
techniques, have led to the identification of many potential
factors as biomarkers, which may provide possibilities
for the early detection of lung cancer and personalized
therapy [2]. Several genes were identified as predictive
biomarkers in NSCLC, such as the somatic mutationhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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receptor (EGFR) [3]. L-myc is amplified and expressed
in human small cell lung cancer [4]. Although the
oncogenicity of lung cancer-related genes has been
studied extensively, there is limited knowledge of the
process of malignant transformation and the regulatory
mechanisms of multistep pathogenesis, especially the
regulatory network of lung cancer-related genes, which
urgently need to be studied [5].
MicroRNAs (miRNAs) are small non-coding RNAs
(~23 nt long) that regulate gene expression at the post-
transcriptional level. MiRNAs are encoded by genomic
DNA, transcribed by RNA polymerase II and then
incorporated into a RNA-induced silencing complex
that binds to the 3′-UTR regions of its target mRNAs
to repress translation or enhance degradation [6]. In
recent years, important roles for miRNAs were identified
in developmental timing, tumorigenesis, cell proliferation,
and cell death [6,7]. MiRNAs function as oncogenes
and tumor suppressors, and their regulatory effects in
lung cancer development and progression have been
demonstrated [8-10].
Hsa-let-7a acts as a protective miRNA that suppresses
RAS and other transcriptional factors. Hsa-let-7a expres-
sion is generally reduced in NSCLC patients [11,12].
High expression of hsa-miR-155 was reported to be
associated with poor survival in lung cancer patients
[13]. Hsa-miR-128b directly regulates epidermal growth
factor receptor (EGFR), and loss of heterozygosity of
hsa-miR-128b was detected frequently in NSCLC patients
[14]. Higher tumor miR-92a-2* levels are associated
with decreased survival in patients with small cell lung
cancer. MiRNAs can act as biomarkers of human lung
cancer, and this may have important clinical applications
in prognosis prediction and in predicting the molecular
pathogenesis of cancer, as well as in the development of
targeted therapies [15-17].
At the transcriptional level, transcription factors (TFs)
are the main regulators that control the transcription of
their target genes by binding to specific DNA sequences
in the promoter regions of the genes. TFs and miRNAs
are the two largest families of trans-acting, gene regulatory
molecules in multicellular organisms, and they share a
common regulatory logic [18]. Most genes in a genome
are regulated not by a single factor, but instead by a
synergistic network of trans-acting factors. At the network
level, motifs comprising miRNAs, TFs, and common
target genes were found to be widespread in diverse
organisms from bacteria to human, suggesting that these
motifs serve as basic building blocks of transcription
networks. In our work, we have used the term “motif”
to describe a small group that illustrates the regulation
patterns of a miRNA, a TF, and their target genes.
Common motifs, such as feedforward loops (FFLs) andfeedback loops (FBLs), have been found to play crucial
roles in gene regulation, such as the miR-17 cluster, the
E2F1, and the c-Myc that modulates cellular prolifera-
tion in cancer [19]. Several databases of TF-miRNA
FFLs involved in tumors have been developed [20,21].
Moreover, protein-protein interactions data have been
included to construct regulatory networks for identifying
novel regulatory motifs, such as the four or more node
FFLs [22,23].
Previous studies into the co-regulation between miRNAs
and TFs found a variety of significant network motifs
that were over-represented in the co-regulation network
[24,25], suggesting that the gene regulation system
requires close synergistic regulation by transcriptional
and post-transcriptional layers. However, the miRNA-TF
synergistic effect may not be limited only to the FFLs.
Non-loop forms, such as the cascaded form, which have
also helped in understanding the regulatory mechanism,
should be considered. Therefore, in this study, we have
identified multiple types of motifs, including FFLs, miRNA-
or TF-mediated FBLs, and miRNA or TF-mediated
cascaded patterns.
Here, we used comprehensive data sources and algo-
rithms to predict regulatory relationships of miRNAs
and their targets in an attempt to provide the first
miRNA-TF-mediated regulatory network in lung cancer.
We also identified synergistic motifs of miRNAs and
TFs. Several potential major factors were identified in
subnetworks. We have developed an algorithm to predict
the biological functions involved in the human lung cancer
miRNA-TF regulatory network as well as the specific
functions regulated by each synergistic motif. Our results
showed that miRNAs of the same family exhibited similar
regulatory modes, implying that miRNA family members
tended to work together, particularly in regulating TFs.
The miR-17 family (in an FFL with the E2F1and the RB1)
was found to be an important family in the lung cancer
regulation network.
This study provides a framework for constructing a
lung cancer-related synergistic regulatory network and
for analyzing the biological functions of the network.
This approach could be applied easily to study other
cancers, and may provide useful information for laboratory
experiments and target validation.
Results
MiRNA and TF synergistic regulatory network in lung cancer
We collected and curated 1990 human lung cancer-re-
lated genes from several disease-related gene databases
and 1823 genes that were aberrantly expressed in NSCLC
samples. From them, we selected a total of 1002 genes
that met the requirements of lung cancer-related genes
to use in this study. The 100 bootstrapping repetitions
that we conducted on the microarray data showed that
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re-sampled data and the original gene set (1002 genes)
was quite significant, suggesting that our selected lung
cancer-related genes were robust. The ratios of overlap
genes to original genes are listed in Additional file 1:
Table S1.
By combining multiple algorithms, we obtained the
targets of all the human miRNAs and TFs, and then used
hypergeometric tests to obtain 252 lung cancer-related
miRNAs and 173 TFs. Based on the relationships between
lung cancer miRNAs/TFs and lung cancer genes, we
constructed a lung cancer miRNA-TF synergistic regu-
latory network. The numbers of nodes and regulatory
relations in the network are listed in Table 1.
The results of the node degree distribution analysis
showed that most nodes had low degrees and only a
few nodes had high degrees (Figure 1), which reflected
a scale-free network. Therefore, hub nodes might play
major roles in the synergistic regulatory network. Because
the edges in the networks had directions, we identified
the hub nodes with the highest incoming and outgoing
degrees. As shown in Tables 2 and 3, eight of the top
10 TFs with higher outgoing degrees [26-35] and more
than half of the hub nodes were either well-known lung
cancer regulators, such as MYC and TP53, or related
to lung cancer development and progression, such as
E2F1 and SP1 [13,36-49]. This finding was a preliminary
reflection of the robustness of the network. Notably,
four of the top 10 hub miRNAs belonged to the miR-17
family, namely has-miR-106a/106b/20a/20b, indicating
that these miR-17 family members are vital regulators
in the regulatory network of human lung cancer. The
top 5% of the hub TFs and miRNAs are shown in
Additional file 1: Table S2. Some of the hubs listed
in Tables 2 and 3 did not meet the enrichment test
of hypergeometric cumulative distribution in 1000 ran-
domization tests, suggesting that the hubs were caused
by biological significance rather than by false-positive
miRNA target data.
Synergistic motif identification and subnetwork construction
In the human lung cancer synergistic regulatory network,
we identified a total of eight types of synergistic motifsTable 1 Summary of relationships in the lung cancer-related





amiRNA repression of gene expression.
bmiRNA repression of TF expression.
cTF regulation of gene expression.
dTF regulation of miRNA expression.consisting of a miRNA, a TF, and their synergistically
regulated target genes, including full regulation, miRNA-
or TF-leading synergistic regulation, miRNA- or TF-
mediated FFL regulation, co-regulation, and miRNA- or
TF-mediated cascade regulation. We also identified two
other kinds of regulatory motifs, namely, miRNA sim-
ultaneous regulation and TF simultaneous regulation
(Figure 2). To evaluate the significance of the synergistic
motifs, we ran 10000 random simulations (see Methods).
The results of P-values indicated that eight of the observed
motifs differed significantly from the results expected
by chance (see Table 4 for details). To rank the motif
types, we also calculated Z scores for them. The syner-
gistic regulatory motifs with the highest Z scores were
co-regulation and TF-mediated cascade regulation types;
all were in non-loop formation and all comprised regula-
tory relations that were derived from miRNAs. The motifs
with the lowest Z scores were Motifs X and V, and they
were the only two non-significant motifs with P-values
greater than 0.01.
We performed manual literature mining with the
combined keywords “miRNA&TF&cancer” to confirm
the relationship between the motifs and lung cancer or
other types of cancers. Names of the motif components
(gene, TF, or miRNA) and “prognosis&cancer” were com-
bined as keywords to search for motifs that had predictive
power for prognosis (Table 5). Because all the motifs
were identified in this search, we merged motifs of the
same type into a subnetwork, and consequently obtained
10 subnetworks, which are presented in Figure 3 (sub-
network I) and which are available in Cytoscape format
in the Additional file 2. Based on the motif type, we
named the subnetworks I to X to reflect the motif names.
To find the hub regulators under each regulatory motif
type, we analyzed the degree distributions of the 10
subnetworks. All the subnetworks had the features of
a scale-free network as shown in Figure 1. Therefore,
we extracted the hub nodes of each factor type in all
the subnetworks according to the criteria discussed in
the Methods section. The results are listed them in
Additional file 1: Table S3. To determine the distribution
of the regulators among the 10 subnetworks, we counted
the number of motifs that each regulator participated insynergistic regulatory network





Figure 1 Node degree distribution of the whole network and 10 subnetworks. The X axis is the degree of a node, and the Y axis shows the
number of nodes that correspond to the degree. The 10 small figures are for subnetworks I to X in order. The big figure is for the whole
synergistic regulatory network.
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was involved in an average of 2.377 motifs and 43.7% of
them were in motifs above the average, while each
miRNA was involved in an average of 4.89 motifs and
34.1% of them were in motifs above the average. Notably,
three TFs (STAT1, E2F1, and ESR10) participated in all
motifs and seven miRNAs participated in all motifs,
namely hsa-miR-106a, hsa-miR-20a, hsa-miR-17, hsa-
miR-19b, hsa-miR-381, hsa-miR-21, and hsa-miR-221.
The first four of these miRNAs belong to the miR-17
family, further indicating the important role of the
miR-17 family in the network.Biological functions of the synergistic regulatory
networks and subnetworks
First, mutations in the genes of ten subnetworks were
analyzed. We downloaded somatic mutation profiles
of 538 lung adenocarcinomas (LUAD) and 178 lung
squamous cell carcinomas (LUSC) from The Cancer
Genome Atlas level 2 data. Then, we selected genes in
each subtype with mutation rates greater than 5% as a
mutated gene set. Hypergeometric cumulative distribution
was used to test the enrichment significance for genes
in 10 kinds of motifs. The results showed that the 10
kinds of motifs were all significantly enriched in the
mutated gene set.After obtaining all the synergistic motifs in the human
lung cancer regulatory network, we next examined the
Gene Ontology (GO) biological process (BP) terms and
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways they regulated. We developed an algorithm to
analyze the network functions based on the results of
the BP and pathway enrichment analyses (see Methods).
All enriched terms were scored and sorted in descending
order, and the top 5% were defined as common terms.
A total of 36 common GO terms were identified and
clustered under the following functions: regulation of
apoptosis and programmed cell death, regulation of cel-
lular protein and phosphate metabolic process, receptor
protein signaling pathway, regulation of protein phos-
phorylation and modification process, cell cycle, regula-
tion kinase activity, DNA repair, and metabolic process
(Table 6). The 22 common KEGG pathways that were
identified were similar to the common BP terms (Table 7).
The common pathways were ranked according to their
scores from high to low. The top 10 pathways included
P53 pathway, direct P53 effectors, regulation of telomer-
ase, and cell cycle; and the lowest ranked pathways
included E2F transcription factor network and canonical
Wnt signaling pathway ranked 20 and 22, respectively
(Table 7).
We speculated whether the specific BP terms for each
subnetwork were regulated specifically by each motif type.
Table 3 Top 10 genes, TFs, and miRNAs with highest
in-degree in lung cancer synergistic regulatory network
Top Gene In- degree Supported bya
1 NTRK2 153 PMID: 21466358
2 ACVR2B 146 -
3 PLAG1 142 -
4 RAPH1 131 -
5 IGF1R 127 PMID: 22133293
6 CLCN5 123 -
7 FOXP1 123 PMID: 22904134
8 ACSL4 120 -
9 WHSC1 120 PMID: 22028615
10 ABHD2 120 -
1 E2F3 112 PMID: 16938365
2 ESR1 110 PMID: 18949413
3 PPARA 79 -
4 SMAD7 75 PMID: 21221812
5 ETS1 68 PMID: 17785952
6 MAFG 62 -
7 ETS2 56 PMID: 21922129
8 ARNT 54 PMID: 22645320
9 AHR 53 PMID: 21646808
10 FUBP1 51 PMID: 19258502
1 hsa-miR-129-5p 7 -
2 hsa-miR-19b 7 -
3 hsa-miR-219-5p 7 PMID: 16530703
4 hsa-miR-92a 7 -
5 hsa-miR-301b 6 -
6 hsa-miR-433 6 -
7 hsa-miR-557 6 -
8 hsa-miR-152 5 -
9 hsa-miR-16 5 PMID: 19549910
10 hsa-miR-329 5 -
11 hsa-miR-429 5 PMID: 19759262
aSupported by: published articles in which the gene, TF, or miRNA was
experimentally verified as being related to lung cancer development
and progression.
Table 2 Top 10 miRNAs and TFs with highest out-degree
in lung cancer synergistic regulatory network
Top Regulator Out- degree Supported bya
1 hsa-miR-590-3p 320 -
2 hsa-miR-548c-3p 302 -
3 hsa-miR-570 243 -
4 hsa-miR-340 242 -
5 hsa-miR-495 218 -
6 hsa-miR-106ab 207 PMID: 19209007
7 hsa-miR-106bb 202 -
8 hsa-miR-20ab 201 PMID: 16266980
9 hsa-miR-20bb 200 -
10 hsa-miR-944 200 -
1 MYC 116 PMID: 11720740
2 TP53 95 PMID: 12619108
3 E2F1 73 PMID: 22803943
4 TFAP2A 64 PMID: 22143938
5 SP1 61 PMID: 22158040
6 JUN 59 -
7 E2F4 50 PMID: 19473719
8 HIF1A 48 PMID: 22115707
9 NFKB1 48 -
10 STAT1 44 PMID: 17348819
aSupported by: published articles in which the TF or miRNA was
experimentally verified as being related to lung cancer development
and progression.
bbelongs to the miR-17 family.
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terms were ranked by their enrichment frequency in
the subnetworks and then categorized within each sub-
network. Details of the results are shown in Additional
file 1: Table S5. The functions of the miRNAs in the
lung cancer regulatory network were predicted from
subnetwork VII because it comprised motifs with miRNAs
that simultaneously regulated TFs and genes, while TFs
that regulated genes or miRNAs were not included in
these motifs. The predicted functions were regulation
of fibroblast growth factor signaling pathway, inositol
lipid-mediated signaling, response to insulin stimulus,
MAPK cascade, receptor signaling pathway, cell migration,
DNA replication and metabolism, phosphorylation, enzy-
matic activity, and meiosis. Similarly, the functions of the
TFs were predicted from subnetwork X; they included
regulation of protein metabolic process, apoptosis and
programmed cell death, gene expression, phosphorylation,
and regulation of enzyme activity. Each motif in subnet-
work I comprised a FBL and FFL, and not surprisingly,
their specific function was DNA replication, which requires
precise and complex regulation because of its ubiquity
in cells and the multiple enzymes involvement.Interplay of miRNA and TF in the human lung cancer
regulatory network
Of the 252 miRNAs in the regulatory network, 93
(36.9%) were regulated by TFs. Most of these miRNAs
had low in-degree, and only 11.8% (11 of the 93) had
in-degrees greater than 5. Of the 173 TFs in the net-
work, 27 (15.6%) were regulated by miRNAs, and 37.0%
(10 of 27) of them had in-degrees greater than 50. A
total of 57 TFs regulated miRNAs and 244 miRNAs
regulated TFs. On average, each TF was regulated by
9.33 miRNAs, while each miRNA was regulated by
Figure 2 The 10 kinds of motifs identified in this study. The ellipse nodes are the genes; the round rectangle nodes are the miRNAs; and the
triangle nodes are the TFs.
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the interplay between the miRNAs and TFs in the lung
cancer regulatory network, we found that only a small
number of the TFs were regulated by miRNAs at a
high intensity, while most miRNAs were regulated byTable 4 Details of motifs in the lung cancer synergistic regula
Motif Z-valuea/P-valueb Meanc Stdc No
I 4.9847/ 0 27.0475 11.8268 86
II 6.9558/ 0 1417.3280 81.6113 19
III 2.4034/ 0.0097 438.9193 30.8235 51
IV 4.2270/ 0.0001 771.7246 260.5343 18
V 2.3031/ 0.0162 230.3356 87.9953 43
VI 19.9562/ 0 32689.19 290.5763 38
VII 27.6201/ 0 114787.3 1225.9080 14
VIII 2.9824/ 0.0004 19895.26 369.7436 20
IX 8.3071/ 0 12070.81 267.1441 14
X 1.2440/ 0.108 4284.108 155.8588 44
aZ-value was calculated using the formula (2.4.1).
bP-value is the proportion of the 10000 random simulations in which a motif had a
cMean and Std are the average and the standard deviation of motif frequency of th
Motif I: Full regulation; II: TF-leading synergistic regulation; III: miRNA leading synerg
synergistic regulation; VI: synergistic co-regulation; VII: miRNA simultaneous regulat
simultaneous regulation.TFs at a significantly lower intensity (Additional file 1:
Figure S11).
In some subnetworks, the miRNAs that belonged to
the same family tended either to function together or to
synergistically regulate targets. To further clarify thistory network
. of motifs No. of genes No. of TFs No. of miRNA
28 3 12
85 180 22 219
3 176 35 66
73 520 4 13
3 97 4 13
488 422 163 250
8647 928 26 243
995 882 56 88
290 237 27 242
78 414 56 88
larger frequency in the random repeats than real in the data.
e 10000 random repeats.
istic regulation; IV: miRNA feedback synergistic regulation; V: TF feedback
ion; VIII: linear regulation from TF; IX: linear regulation from miRNA; and X: TF
Table 5 Examples of motifs or prognosis components of motifs
Motif Example Supported bya Prognosis Supported by P-valueb
I miR-106a& E2F1 PMID: 18521848 miR-106a &E2F1 &RAD51 PMID:20219352&16166473 &15956972 0.03790692
II miR-27b& ESR1 - miR-181a &TP53 &RUNX3 PMID:20363096&17401424 &15819721 0.001892851
III miR-16& MYC PMID: 22002311 miR-16 &JUN &LPL PMID:21400525&9484827 &21508119 3.311478e-06
IV miR-106a& E2F1 PMID: 22002038 miR-17 &STAT1 &ALDH1A3 PMID:22065543&20581241 &22960273 1.80563e-21
V miR-17& E2F1 PMID: 18171346 miR-21 &ESR1 &CXCL12 PMID:20508945&20109227 0.006603943
VI miR-548& MYC - Let-7d &ATF1 &GSTP1 PMID:21725603&22631637 &22045684 3.35018e-07
VII miR-20b& ESR1 PMID: 22002038 miR-200c &E2F3 &ALDH1A3 PMID:20579395&15122326 &23436614 6.592982e-22
VIII miR-152& POU2F1 PMID: 21712563 miR-141 &SOX2 & CXCL12 PMID:21445232&20532662 &16631235 1.471662e-21
IX miR-19a& ESR1 PMID: 20080637 CTNNB1 & miR-21 & SMAD7 PMID:17949785&20508945 &12584741 0.0002268908
X miR-34c-5p& MYC PMID: 22585994 GADD45A& miR-34 & P53 PMID:12171872&19736307 &22978804 2.885798e-06
aSupported by: published articles in which the gene, TF, or miRNA was experimentally verified as working together or have a prognosis function.
bP-value: the P-value of hypergeometric cumulative distribution to test whether the motifs were enriched with gene mutations.
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based on the regulatory relations between the 252 miR-
NAs and 173 TFs. We found that 10 miRNA families in-
volving 45 miRNAs were clustered and that the miRNAs
from one family had similar target TFs (Figure 4).Figure 3 Lung cancer-related miRNA-TF synergistic regulatory subnet
are the miRNAs; and the triangle nodes are the TFs. Green nodes: down-re
transcriptional activation/repression; T-shape edge: miRNA repression; andA model of the miR-17 family, RB1, and E2F1 motif in
lung cancer proliferation
In subnetwork I, we discovered the predicted interactions
between the miR-17 family and E2F1 for the first time
(Additional file 1: Table S6). Interestingly, six memberswork I. The ellipse nodes are the genes; the round rectangle nodes
gulated nodes; red nodes: up-regulated nodes; arrow shape edge:
dash line: a feedback loop.
Table 6 Biology process terms regulated by the miRNA-TF synergistic regulatory network
GO term Annotation Ranka In motifsb
GO:0042981 Regulation of apoptosis 1 10
GO:0032268 Regulation of cellular protein metabolic process 2 10
GO:0007167 Enzyme linked receptor protein signaling pathway 3 9/I
GO:0031399 Regulation of protein modification process 4 10
GO:0042325 Regulation of phosphorylation 5 10
GO:0019220 Regulation of phosphate metabolic process 6 10
GO:0051329 Interface of mitotic cell cycle 7 10
GO:0000082 G1/S transition of mitotic cell cycle 8 9/IV
GO:0001932 Regulation of protein phosphorylation 9 10
GO:0007169 Transmembrane receptor protein tyrosine kinase signaling pathway 10 9/I
GO:0071156 Regulation of cell cycle arrest 11 9/IV
GO:0045859 Regulation of protein kinase activity 12 10
GO:0000075 Cell cycle checkpoint 13 9/IV
GO:0006259 DNA metabolic process 14 10
GO:0006281 DNA repair 15 9/IV
GO:0043549 Regulation of kinase activity 16 10
GO:2000045 Regulation of G1/S transition of mitotic cell cycle 17 9/IV
GO:0000084 S phase of mitotic cell cycle 18 9/IV
GO:0051320 S phase 19 9/IV
GO:0007093 Mitotic cell cycle checkpoint 20 9/IV
GO:0031575 Mitotic cell cycle G1/S transition checkpoint 21 8/III, IV
GO:0071779 G1/S transition checkpoint 22 8/III, IV
GO:0006468 Protein phosphorylation 23 9/I
GO:0043066 Negative regulation of apoptosis 24 9/I
GO:0043069 Negative regulation of programmed cell death 25 9/I
GO:0031328 Positive regulation of cellular biosynthetic process 26 9/I
GO:0071900 Regulation of protein serine/threonine kinase activity 27 9/I
GO:0009968 Negative regulation of signal transduction 28 9/I
GO:0048011 Nerve growth factor receptor signaling pathway 29 9/I
GO:0046777 Protein autophosphorylation 30 7/I, II, V
GO:0006355 Regulation of transcription, DNA-dependent 31 9/I
GO:2001141 Regulation of RNA biosynthetic process 32 9/I
GO:0009967 Positive regulation of signal transduction 33 8/I, V
GO:0006357 Regulation of transcription from RNA polymerase II promoter 34 9/I
GO:0043065 Positive regulation of apoptosis 35 9/I
GO:0045893 Positive regulation of transcription, DNA-dependent 36 8/I,III
aRank: is the rank number calculated using the formula (2.7.1) based on the number of occurrences of the GO terms among all the assigned terms.
bIn motifs: is how many motif types (subnetworks) were assigned the corresponding GO term. The roman number(s) following the slash indicate the subnetwork
(s) in which the corresponding GO term was not found.
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clustered in one group. The miR-17 family and E2F1
formed a FBL, which was a clique. A similar phenomenon
was reported for the miR-17-92 cluster (miR-17/20a/18a/
19a/19b-1/92-1), which forms a FBL with E2F1, and plays
roles in regulating cellular proliferation and apoptosis.
The interactions between the miR-17-92 cluster andE2F1 have been verified experimentally [50-54]. The
miR-17 family and the miR-17-92 cluster have two
shared members, miR-17 and miR-20a, both of which
were confirmed to interact with E2F1. For the other
four members of the miR-17 family, we performed a
sequence alignment to examine how likely they were to
interact with E2F1. The conserved sequence of E2F1
Table 7 Pathways regulated by miRNA-TF synergistic
regulatory network
Pathway name Ranka In motifsb
p53 pathway 1 8
Direct p53 effectors 2 8
Regulation of Telomerase 3 7
Hypoxia and oxygen homeostasis
regulation of HIF-1-alpha
4 8
Arf6 signaling events 5 8
Cell Cycle, Mitotic 6 7
S Phase 7 6
Synthesis of DNA 8 7
DNA Replication 9 6
Regulation of DNA replication 13 5
G1/S Transition 10 6
IGF1 pathway 11 6
Orc1 removal from chromatin 12 5
Switching of origins to a post-reflective state 14 5
Removal of licensing factors from origins 15 5
Signaling events regulated by Ret tyrosine kinase 16 4
EphrinA-EPHA pathway 17 3
E-cadherin signaling events 18 7
FOXA transcription factor networks 19 6
E2F transcription factor network 20 7
Neurotrophic factor-mediated Trk receptor signaling 21 9
Canonical Wnt signaling pathway 22 7
aRank: is the rank number calculated using the formula (2.7.1) based on the
number of occurrences of the pathways among all the assigned pathways.
bIn motifs: is how many motif subnetworks were assigned the
corresponding pathways.
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troglodytes, Rattus norvegicus and Bos taurus) was aligned
to the mature sequences of the six members of the
miR-17 family. All miR-17 family members shared 8–15
bases with the E2F1 conserved sequence (Additional
file 1), and their interaction was predicted by at least
five algorithms (Additional file 1: Table S6), supporting
the high possibility of an interaction between the miR-17
family and E2F1.
The RB1 tumor suppressor negatively regulates the cell
cycle and is inactivated in a wide range of human tumors
[55]. In subnetwork I, RB1 was targeted by members of
the miR-17 family (Additional file 1: Table S6) and E2F1,
while the miR-17 family members and E2F1 targeted each
other, thereby forming an FFL. By analyzing the miRNA
expression profiles of NSCLC patients, we found that five
miR-17 family members were significantly overexpressed,
the expression of RB1 was significantly down-regulated,
and E2F1 expression was not significantly different
(Additional file 1: Table S7). MiR-20b was the exception tothis because no probe was detected. Next, we examined
the mechanism by which the miR-17 family regulates
cell cycle and tumor progression in lung cancer using a
hypothetical model. The interaction between the pRb
proteins and the E2F TF family plays a central role in
regulating cell cycle progression by controlling the
expression of E2F-dependent cell cycle genes [56]. The
overexpressed miR-17 family may directly decrease the
translation of RB1, thereby lowering the expression of
the RB1 protein. In G0 or early G1 cells, Rb protein,
which has been functionally inactivated by transcriptional
suppression, releases the transactivation domains of E2F
and activates the expression of genes that encode products
necessary for S-phase progression [50]. Moreover, E2F1
promotes the transcription of the miR-17 family, which
causes overexpression of the miR-17 family members,
thereby governing cell cycle and proliferation of lung
tumors by targeting RB1 protein.
Discussion
Here we constructed the first lung cancer-related miRNA-
TF synergistic regulatory network of lung cancer. We
identified 10 types of motifs and constructed 10 sub-
networks. More than half of the putative hub nodes
were verified by examining other published works, which
indicated the robustness of the network. We developed
an algorithm to understand the common and specific
functions of these networks. Finally, we proposed a
hypothetical model to explain the role of the miR-17
family in regulating cell cycle and tumor progression by
targeting the RB1 protein in NSCLC.
In the human miRNA-TF synergistic regulatory network
and subnetworks, hub genes and hub miRNAs were
identified. Most either were known lung cancer-related
factors or were reported to play important roles in lung
cancer. The hubs with highest out-degrees in the regulatory
network, Myc, TP53, and E2F1, are TFs that play roles in
apoptosis, cell proliferation, and lung tumor development.
The amplification and overexpression of Myc has been
detected in lung cancer of different histologic subtypes
[26]. TP53 encodes tumor protein p53, abnormalities of
which are frequently found in lung cancers [27]. E2F1
overexpression was reported produce more aggressive
tumors with a high proliferation rate during the pro-
gression of NSCLC [57]. MiR-17/106a/20a/93/34a were
the hubs of many subnetworks, and four of them
belong to the miR-17 family. MiR-17 and miR-20a were
reported to induce apoptosis in lung cancer cells [35]
and miR-34 s was found to be dramatically down-
regulated in NSCLC [58].
In this work, we proposed a model to predict the regula-
tory role of the miR-17 family in the cell cycle via RB1 and
E2F1. In the model, five out of six miR-17 family members
were significantly overexpressed in NSCLC cells where they
Figure 4 Heatmap of miRNA-TF hierarchical clustering. Green:
miRNAs regulated by TFs; blue: non-regulatory relations; dark pink:
regulations to TFs of miRNAs that were clustered closely in the
hierarchical tree and belonged to a same family. Square brackets:
zoom in view of the miRNAs on the left of the figure. MiRNAs in
square brackets belonged to different families.
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sible for the G1 checkpoint and blockage of S-phase entry
and cell growth. Hesan et al. [59] confirmed the up-
regulation of four members of the miR-17 family in colo-
rectal carcinoma tissues and showed that they promote
cell proliferation and tumor growth by targeting the
RND3 tumor suppressor gene. A similar group, the miR-
17-92 cluster with two members that were common
with the miR-17 family, had diverse functions in the
regulation of cellular differentiation, proliferation, and
apoptosis. The two common members, miR-17 and miR-
20a, were shown to temper an E2F1-induced G1 check-
point to regulate cell cycle progression [50]. Furthermore,
the E2F and the miR-17-92 cluster could form FBLs
[51], and in the cancer regulation network, FBLs in-
volving miR-17-92, E2F and MYC have been reported
[52]. We checked the interactive relations of the miR-
17 family with E2F1 and RB1 by sequence alignment
and found a strong possibility of their interactions. More-
over, many regulatory relationships support our predictive
model of the miR-17 family, E2F1, and RB1 motif, which
demonstrates the effectiveness of our regulatory network.
After identifying the miRNA-TF synergistic motifs, we
calculated their significance and Z-values, and ranked the
motifs according to their Z scores. The first-ranked
Motif VII was more significant than the second-ranked
Motif VI, possibly because of the availability of abundant
miRNA regulation data but insufficient TF regulation
data. One reason that Motif VI was found to be the most
significant regulatory motif in the network may be that
genes are first regulated by TFs at the transcription level
and then by miRNAs at the post-transcription level; thus,
genes are significantly regulated by TFs and miRNAs
separately at different times and in different locations
in the cell. By comparing two Motifs, II and III, and by
examining the regulatory directions between the miRNAs
and TFs, we found that miRNAs tended to be significantly
regulated by TFs rather than regulate TFs. This obser-
vation is despite the fact that data on the - targets of
TFs are limited, while much more data on the targets
of miRNAs are available. Therefore, we inferred that TFs
play a dominant role in FFL regulation. This assumption
is supported by the results of another study, which found
that TFs held dominant positions in the global regulatory
system (i.e. at the transcriptional level) compared with
the miRNAs at the downstream positions (i.e. at the
post-transcriptional level) [23]. Between the linear motifs
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which indicated that genes tended to be regulated directly
by TFs, while miRNAs tended to regulate TFs while they
were being formed rather than act as a mediated regulator
between TFs and their target genes.
The expression level analysis of genes and miRNAs
may help in understanding the regulatory mechanisms;
therefore, the differentially expressed genes in our networks
further investigated. In general, we found that up-regulated
miRNAs down-regulated their target genes by degrading
them at the transcript level or by repressing protein
production at the translational level. We also observed
the reverse, in which down-regulated miRNAs led to
up-regulated target genes. However, down-regulated
miRNAs that down-regulated their target genes and
up-regulated miRNAs that up-regulated their target
genes were also observed in our network. This may be
because the expression levels of genes or miRNAs are
determined by multiple factors, including environment,
heredity, copy number variations, and epigenetics. Thus,
miRNAs and TFs may influence expression to a great
degree rather than being the decisive factors.
In this study, we analyzed the regulation of genes by
miRNAs and TFs, but did not consider gene-to-gene rela-
tionships. Cui et al. [60,61] studied the relationship among
oncogenes in the context of activity/inhibitory motifs and
compared the number of mutant genes and miRNA target
genes in each type of motif. In the future, we will examine
the activation, inhibition, and physical interactions among
the genes in regulatory networks, and discuss the regularity
role of miRNAs, TFs, and motifs. Our future studies will
contribute to uncovering the principles of miRNA regula-
tion in signal transduction networks.
Conclusions
In summary, our established miRNA and TF synergistic
regulatory network in NSCLC has provided clues about
the regulatory mechanisms of lung cancer and infor-
mation that will help identify the core regulators. Nearly
half of the hub regulators, as well as the proposed
regulatory motifs, were confirmed by literature searches,
which indicated the effectiveness and rationality of the
network construction. The most significant motifs were
of the co-regulation and TF-mediated cascade regulation
types. While cooperating with miRNAs, TFs tended to
play a dominant role in FFL regulations. We also devel-
oped an algorithm to analyze the functions of the human
lung cancer miRNA-TF regulatory network and subnet-
works. According to the full regulation subnetwork and
expression analysis, we proposed a predictive model of
the miR-17 family, E2F1 and RB1 in the regulation of cell
cycle and cellular proliferation. Our study will provide
valuable information for lung cancer investigators to
identify critical elements and regulatory motifs for abetter understanding of the regulatory mechanisms or
for designing future experimental studies of lung cancer.
Methods
Lung cancer-related genes
Lung cancer-related genes were collected using an inte-
grated strategy as follows: 1) We retrieved published
genes with somatic mutation or vital for lung cancer from
five well-established cancer- and disease-related gene
databases, namely Phenopedia [62], Cosmic [63], GAD
[64], TGDB, and OMIM [65]. 2) Aberrantly expressed
genes were obtained from two gene expression profiles
of NSCLC samples published in the NCBI GEO database
[66], namely, [GEO:GSE2088] and [GEO:GSE11969]. In
the profile GSE2088, 48 squamous cell carcinoma sam-
ples, nine adenocarcinoma samples and 30 normal
samples were investigated. We used only 125 NSCLC
samples from the profile GSE11969, including 35 squamous
cell carcinoma samples, 90 adenocarcinoma samples,
and five normal samples, and ignored samples with
other subtype. We carried out a profile preprocessing
step on the samples, which included filtering out data
with more than 5% missing values, combining probes
of the same gene, and then filling missing values using
the K-neighbors algorithm. We screened differentially
expressed genes using the criteria of fold change value >
1.5 and false discovery rate (FDR) < 0.01. Differentially
expressed genes that were common to the two profiles
were included. 3) We selected the intersection of the two
gene sets obtained from the two previous steps to use in
the present study (Figure 5A). Because gene lists can
change when re-sampling is applied to microarray data
[67], we conducted a bootstrapping procedure with 100
replications on the microarray data to confirm the
robustness of the selected lung cancer-related genes.
Target prediction of miRNAs and TFs
For miRNA target prediction, we combined 10 popular
databases or algorithms, namely, miRanda, TargetScan,
PicTar5, PITA, DIANA-microT, mirSVR, RNA22, RNA-
hybrid, MirTarget2, and TargetMiner (Additional file 1:
Table S8). To decrease the number of false-positive results,
only miRNA–mRNA interactions predicted by at least
three of the algorithms were accepted as positive. TFs were
treated as genes when predicting miRNA–TF regulations.
TFs and their experimentally proven targets were re-
trieved from four databases: ORegAnno [68], Pazar [69],
Transfac [70], and Tred [71]. To ensure that the results
were complete, we used a union set of all the retrieved data.
MiRNA precursor sequences were obtained from the
miRBase database. We selected the 2-kb upstream regions
of the pre-miRNAs as their putative promoter regions,
and then searched the sequences for TF binding sites
using the UCSC genome browser (Z score =2.33) [72].
Figure 5 Workflow of data collection, miRNA-TF synergistic
regulatory network construction, and motif identification. A:
Lung cancer-related gene collection. Lung cancer genes were
obtained from five databases, differential expressed genes in two
microarray datasets were calculated, and the overlapped set were
used in the present study. B, C, and D showed the data source or
algorithms of regulator-target relations. E: Workflow of synergistic
regulatory network construction and motif identification. Elements
with a star mark ‘*’ are ‘lung cancer related-’. First, by Gene* from
step A and miRNA target relations from step B, we obtained miRNA*
using a hypergeometric test. After a similar procedure for getting
TF*, we combined any two of Gene*, miRNA*, and TF*with their
regulatory relations to obtain four types of regulatory relation*. Then,
we merged them to construct the miRNA-TF synergistic regulatory
network*. Last, 10 motif types were identified.
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human, rat, and mouse. We also incorporated experimen-
tally supported TF–miRNA regulatory relations that were
curated manually from large numbers of published papers
[25] and from TransmiR [21] (Figure 5C).
Significant lung cancer-related miRNAs and TFs
After obtaining the miRNA/TF and targets relations, we
calculated the regulators whose targets were significantly
enriched with lung cancer genes using the hypergeometric














where, M is the total number of all human genes in the hu-
man genome, k is the number of lung cancer-related genes,
N is the number of target genes for a certain miRNA (or
TF), and x is the number of target genes of a certain
miRNA (or TF) that overlapped with lung cancer-related
genes. To avoid the effect from false-positives in the
miRNA target data, we conducted randomization tests to
ensure the biological significance of the identified lung
cancer-related miRNAs and TFs. Instead of using 1002 lung
cancer-related genes to enrich each of the miRNAs and
TFs, we randomly selected 1002 genes from all the coding
genes in the human genome for enrichment, and this pro-
cedure was repeated 1000 times.
Motif identification and statistics test
Based on the regulatory relationships that we predicted,
network motifs of miRNA-TF synergistically regulatory
patterns were identified, including the FFLs and non-loop
form (Figure 5E). We performed statistical analysis to
estimate the significance of each motif type. Specifically,
in random networks, each node maintained the number
of incoming and outgoing edges that they had in the
corresponding node in the real network. Then, the
number of each type of motifs was counted, and this was
repeated 10000 times. The significance value (P-value)
of one motif type indicates the proportion of the 10000
repeats when the motif was observed in the random
networks was no less than its appearance in the real




where, Nhigh is the number of random times that an ac-
quired motif was more than or equal to the real network,
and Nrandom is 10000.
We also calculated Z scores for all the motif types to
estimate by how many standard deviations an observation




where, Nreal and Nmean are the number of motifs observed
in the real synergistic regulatory network and their mean
occurrence in the random networks, respectively. SD is
the standard deviation of the number of motifs in the
random networks.
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All network motifs of the same type were merged to
construct a motif-specific subnetwork (for example, all
FFLs were merged to form the FFL subnetwork) and
then the subnetworks were visualized by the Cytoscape
software [73]. When network sizes were greatly different
from one another, we defined hub nodes as the top 5%
highest-degree nodes of the miRNAs, TFs, and genes in
both the subnetwork and whole network.
Expression level analysis of miRNAs, TFs, and genes
MiRNA and gene expression profiles were downloaded
from the NCBI Gene Expression Omnibus (GEO), and
differentially expressed genes were calculated using the
significance analysis of microarrays (SAM) software
[74] with the FDR set to less than 1%. The union set of
differentially expressed genes in the GSE2088 and
GSE11969 datasets was used to determine the lung
cancer-related genes, while the intersection was shown
in different colors in the motif-specific subnetwork.
The miRNA expression profiles from the GSE27705
dataset, which included 20 NSCLC samples and 10
normal samples, were used to identify up- or down-
regulated expressed miRNAs.
BP and pathway analysis of the genes in the human
lung cancer synergistic regulatory network and
synergistic subnetworks
For the function analysis of each subnetwork, we developed
an algorithm to obtain the most representative functions
among the numerous GO BP terms and KEGG pathways
after BP and pathway enrichment analysis. For example,
for the BP function analysis of subnetworki (Motifi) the
algorithm: 1) found the target gene set shared by each
miRNA-TF pair, which contained no less than three
genes; 2) all target gene sets were enriched with BP
terms by the hypergeometric test with P-value adjustment
by FDR (the cutoff of P-value was 0.005); and 3) the
frequency that each BP term was enriched was counted
and represented as Frequenti (i∈[1,10]), and all enriched
terms were ranked in descending order according to
their frequency value, so that the rank number of each
BP term, represented as Motifi-rank, could be obtained.
Terms with high commonality existed in most subnet-
works and ranked high in each subnetwork and, there-
fore, could be assumed to represent the main functions





motif i−rank  motif i−stagenumber ð4Þ
where, stagenumber is the number of stages in motifi. The
terms with the highest top 5% score were regarded ascommon terms, and were used to represent the functions
of the whole regulatory network. We then removed the
common terms from each subnetwork and ranked the
remaining terms to identify the specific functions of each
subnetwork. Pathway function analysis was conducted
using the same procedure.
Hierarchical clustering and sequence alignment
In our analysis of the interplay between miRNAs and
TFs, two-way clustering of the regulators was performed
using Cluster 3.0 software [75] and the resultant heatmap
was viewed using TreeView. MiRNA family information
was obtained from miRBase [76]. Multiple sequences
were aligned using ClustalW2 software in the analysis
tools framework at EMBL-EBI [77].
Additional files
Additional file 1: Table S1. Is provided as the ratio of overlap genes
and original genes after bootstrappings; Table S2 is the hub TFs and
miRNAs of lung cancer synergistic regulatory network; Table S3 is the
hub miRNAs and TFs of subnetwork Ito X; Table S4 is the count of motif
types (subnetworks) miRNAs or TFs belong to; Table S5 shows specific
functions of miRNA-TF regulatory subnetwork Ito X; Table S6 indicates
target genes (E2F1 and RB1) predictive results of the miR-17 family; Table
S7 is provided as differential expression analysis of the miR-17 family and
RB1 by SAM; Table S8 is a list of miRNA-target relation predictive algo-
rithms and databases used in our work.
Additional file 2: miRNA-TF synergetic regulatory subnetwork I to X
in order.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XY designed the study, LK, LZ and ZN performed the research, LY, ZY, QF
and ZR analyzed the data, and LZ and LK wrote the manuscript. All authors
have read and approved the final version.
Authors’ information
Kening Li, Zihui Li and Ning Zhao considered as co-first authors.
Acknowledgements
This work was supported in part by the National Natural Science Foundation of
China (Grant No. 81372492), the Natural Science Foundation of Heilongjiang
Province (Grant No. D201116), the Postdoctoral science-research developmental
foundation of Heilongjiang Province (Grant No. LBH-Q11044), and the Innovation
Research Fund for Graduate Students of Heilongjiang Province (YJSCX2012-
211HLJ). We thank Shanzhen Zhang for the programming used in identifying mo-
tifs. We thank Yingying Wang for assistance with collecting the regulatory data.
Author details
1College of Bioinformatics Science and Technology, Harbin Medical
University, Harbin 150081, China. 2Institute of System Engineering, Harbin
University of Commerce, Harbin 150028, China.
Received: 10 June 2013 Accepted: 4 November 2013
Published: 7 November 2013
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA: a cancer
journal for clinicians 2012, 62:10–29.
2. Chen HY, Yu SL, Li KC, Yang PC: Biomarkers and transcriptome profiling of
lung cancer. Respirology 2012, 17:620–626.
Li et al. BMC Systems Biology 2013, 7:122 Page 14 of 15
http://www.biomedcentral.com/1752-0509/7/1223. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S:
Somatic EGFR mutation and gene copy gain as predictive biomarkers for
response to tyrosine kinase inhibitors in non-small cell lung cancer.
Clin Cancer Res 2010, 16:291–303.
4. Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, McBride
OW, Bertness V, Hollis GF, Minna JD: L-myc, a new myc-related gene
amplified and expressed in human small cell lung cancer. Nature
1985, 318:69–73.
5. Ye H, Liu X, Lv M, Wu Y, Kuang S, Gong J, Yuan P, Zhong Z, Li Q, Jia H, et al:
MicroRNA and transcription factor co-regulatory network analysis reveals
miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia.
Nucleic Acids Res 2012, 40:5201–5214.
6. Ambros V: The functions of animal microRNAs. Nature 2004, 431:350–355.
7. Schickel R, Boyerinas B, Park SM, Peter ME: MicroRNAs: key players in the
immune system, differentiation, tumorigenesis and cell death.
Oncogene 2008, 27:5959–5974.
8. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and
tumor suppressors. Dev Biol 2007, 302:1–12.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A,
Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify
human cancers. Nature 2005, 435:834–838.
10. Khoshnaw SM, Green AR, Powe DG, Ellis IO: MicroRNA involvement in the
pathogenesis and management of breast cancer. J Clin Pathol 2009,
62:422–428.
11. Grosshans H, Johnson T, Reinert KL, Gerstein M, Slack FJ: The temporal
patterning microRNA let-7 regulates several transcription factors at the
larval to adult transition in C. elegans. Dev Cell 2005, 8:321–330.
12. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H,
Harano T, Yatabe Y, Nagino M, Nimura Y, et al: Reduced expression of the
let-7 microRNAs in human lung cancers in association with shortened
postoperative survival. Cancer Res 2004, 64:3753–3756.
13. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M,
Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA
molecular profiles in lung cancer diagnosis and prognosis. Cancer cell
2006, 9:189–198.
14. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA,
Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, et al: EGFR regula-
tion by microRNA in lung cancer: correlation with clinical response
and survival to gefitinib and EGFR expression in cell lines. Ann Oncol
2008, 19:1053–1059.
15. Bartels CL, Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer.
Clin Chem 2009, 55:623–631.
16. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG: MicroRNA
classifiers for predicting prognosis of squamous cell lung cancer.
Cancer Res 2009, 69:5776–5783.
17. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ,
Lee YC, Chen HS, et al: MicroRNA signature predicts survival and relapse
in lung cancer. Cancer cell 2008, 13:48–57.
18. Hobert O: Gene regulation by transcription factors and microRNAs.
Science 2008, 319:1785–1786.
19. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-regulated
microRNAs modulate E2F1 expression. Nature 2005, 435:839–843.
20. El Baroudi M, Cora D, Bosia C, Osella M, Caselle M: A curated database of
miRNA mediated feed-forward loops involving MYC as master regulator.
PloS one 2011, 6:e14742.
21. Wang J, Lu M, Qiu C, Cui Q: TransmiR: a transcription factor-microRNA
regulation database. Nucleic acids Res 2010, 38:D119–122.
22. Sun J, Gong X, Purow B, Zhao Z: Uncovering MicroRNA and Transcription
Factor Mediated Regulatory Networks in Glioblastoma. PLoS Comput Biol
2012, 8:e1002488.
23. Lin CC, Chen YJ, Chen CY, Oyang YJ, Juan HF, Huang HC: Crosstalk
between transcription factors and microRNAs in human protein
interaction network. BMC Syst Biol 2012, 6:18.
24. Chen CY, Chen ST, Fuh CS, Juan HF, Huang HC: Coregulation of
transcription factors and microRNAs in human transcriptional regulatory
network. BMC bioinformatics 2011, 12(Suppl 1):S41.
25. Qiu C, Wang J, Yao P, Wang E, Cui Q: microRNA evolution in a human
transcription factor and microRNA regulatory network. BMC Syst Biol
2010, 4:90.
26. Zajac-Kaye M: Myc oncogene: a key component in cell cycle regulation
and its implication for lung cancer. Lung Cancer 2001, 34(Suppl 2):S43–46.27. Toyooka S, Tsuda T, Gazdar AF: The TP53 gene, tobacco exposure, and
lung cancer. Human mutation 2003, 21:229–239.
28. Duan HY, Cao JX, Qi JJ, Wu GS, Li SY, An GS, Jia HT, Cai WW, Ni JH: E2F1
enhances 8-chloro-adenosine-induced G2/M arrest and apoptosis in
A549 and H1299 lung cancer cells. Biochemistry Biokhimiia 2012,
77:261–269.
29. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP: DNA
methylation biomarkers for lung cancer. Tumour Biol 2012, 33:287–296.
30. Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC, Chang WC, Hung JJ: Sp1
expression regulates lung tumor progression. Oncogene 2012, 31:3973–3988.
31. Bankovic J, Stojsic J, Jovanovic D, Andjelkovic T, Milinkovic V, Ruzdijic S,
Tanic N: Identification of genes associated with non-small-cell lung
cancer promotion and progression. Lung Cancer 2010, 67:151–159.
32. Munksgaard Persson M, Johansson ME, Monsef N, Planck M, Beckman S,
Seckl MJ, Ronnstrand L, Pahlman S, Pettersson HM: HIF-2alpha expression
is suppressed in SCLC cells, which survive in moderate and severe
hypoxia when HIF-1alpha is repressed. Am J Pathol 2012, 180:494–504.
33. Li J, Yu B, Song L, Eschrich S, Haura EB: Effects of IFN-gamma and Stat1 on
gene expression, growth, and survival in non-small cell lung cancer cells.
J Interferon Cytokine Res 2007, 27:209–220.
34. Navarro A, Marrades RM, Vinolas N, Quera A, Agusti C, Huerta A, Ramirez J,
Torres A, Monzo M: MicroRNAs expressed during lung cancer
development are expressed in human pseudoglandular lung
embryogenesis. Oncology 2009, 76:162–169.
35. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S,
Yatabe Y, Kawahara K, Sekido Y, Takahashi T: A polycistronic microRNA
cluster, miR-17-92, is overexpressed in human lung cancers and
enhances cell proliferation. Cancer research 2005, 65:9628–9632.
36. Terry J, De Luca A, Leung S, Peacock G, Wang Y, Elliot WM, Huntsman D:
Immunohistochemical expression of neurotrophic tyrosine kinase
receptors 1 and 2 in lung carcinoma: potential discriminators between
squamous and nonsquamous subtypes. Arch Pathol Lab Med 2011,
135:433–439.
37. Nakagawa M, Uramoto H, Oka S, Chikaishi Y, Iwanami T, Shimokawa H, So T,
Hanagiri T, Tanaka F: Clinical significance of IGF1R expression in non-small-
cell lung cancer. Clin Lung Cancer 2012, 13:136–142.
38. Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J: High expression of FoxP1
is associated with improved survival in patients with non-small cell lung
cancer. Am J Clin Pathol 2012, 138:230–235.
39. Toyokawa G, Cho HS, Masuda K, Yamane Y, Yoshimatsu M, Hayami S,
Takawa M, Iwai Y, Daigo Y, Tsuchiya E, et al: Histone lysine
methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in
human carcinogenesis through regulation of the Wnt pathway.
Neoplasia 2011, 13:887–898.
40. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A,
Brunner T, Vassella E: miR-15a and miR-16 are implicated in cell cycle
regulation in a Rb-dependent manner and are frequently deleted or
down-regulated in non-small cell lung cancer. Cancer Res 2009,
69:5553–5559.
41. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ,
Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM: Contextual
extracellular cues promote tumor cell EMT and metastasis by regulating
miR-200 family expression. Genes & development 2009, 23:2140–2151.
42. Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, Fletcher A,
Roe T, Clark J, Joshi A, Norman A, et al: Nuclear overexpression of the
E2F3 transcription factor in human lung cancer. Lung Cancer 2006,
54:155–162.
43. Suga Y, Miyajima K, Oikawa T, Maeda J, Usuda J, Kajiwara N, Ohira T, Uchida
O, Tsuboi M, Hirano T, et al: Quantitative p16 and ESR1 methylation in the
peripheral blood of patients with non-small cell lung cancer.
Oncology Rep 2008, 20:1137–1142.
44. Li X, Yang XX, Hu NY, Sun JZ, Li FX, Li M: A risk-associated single nucleo-
tide polymorphism of SMAD7 is common to colorectal, gastric, and lung
cancers in a Han Chinese population. Mol Biol Rep 2011, 38:5093–5097.
45. Yamaguchi E, Nakayama T, Nanashima A, Matsumoto K, Yasutake T, Sekine I,
Nagayasu T: Ets-1 proto-oncogene as a potential predictor for poor prog-
nosis of lung adenocarcinoma. Tohoku J Exp Med 2007, 213:41–50.
46. Bai J, Hu S: Transcriptome network analysis reveals potential candidate
genes for squamous lung cancer. Int J Mol Med 2012, 29:95–101.
47. Yan Z, Shah PK, Amin SB, Samur MK, Huang N, Wang X, Misra V, Ji H,
Gabuzda D, Li C: Integrative analysis of gene and miRNA expression
Li et al. BMC Systems Biology 2013, 7:122 Page 15 of 15
http://www.biomedcentral.com/1752-0509/7/122profiles with transcription factor-miRNA feed-forward loops identifies
regulators in human cancers. Nucleic acids Res 2012, 40:e135.
48. Chiba T, Uchi H, Yasukawa F, Furue M: Role of the arylhydrocarbon receptor
in lung disease. Int Arch Allergy Immunol 2011, 155(Suppl 1):129–134.
49. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M,
Hoffmann H, Penzel R, et al: Coordinated expression of stathmin family
members by far upstream sequence element-binding protein-1 increases
motility in non-small cell lung cancer. Cancer Res 2009, 69:2234–2243.
50. Pickering MT, Stadler BM, Kowalik TF: miR-17 and miR-20a temper an
E2F1-induced G1 checkpoint to regulate cell cycle progression.
Oncogene 2009, 28:140–145.
51. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F,
Ferbeyre G, Chartrand P: An E2F/miR-20a autoregulatory feedback loop.
J Biol Chem 2007, 282:2135–2143.
52. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB: MicroRNA
regulation of a cancer network: consequences of the feedback loops
involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA 2008,
105:19678–19683.
53. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM,
MacPherson D: miR-17 92 cooperates with RB pathway mutations to
promote retinoblastoma. Genes & development 2011, 25:1734–1745.
54. Olive V, Jiang I, He L: mir-17-92, a cluster of miRNAs in the midst of the
cancer network. Int J Biochem Cell Biol 2010, 42:1348–1354.
55. Giacinti C, Giordano A: RB and cell cycle progression. Oncogene 2006,
25:5220–5227.
56. Macaluso M, Montanari M, Giordano A: Rb family proteins as modulators
of gene expression and new aspects regarding the interaction with
chromatin remodeling enzymes. Oncogene 2006, 25:5263–5267.
57. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, Wada H: E2F1
overexpression correlates with thymidylate synthase and survivin gene
expressions and tumor proliferation in non small-cell lung cancer.
Clin Cancer Res 2007, 13:6938–6946.
58. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y,
Giordano TJ, Qin ZS, Moore BB, et al: p53-mediated activation of miRNA34
candidate tumor-suppressor genes. Curr Biol 2007, 17:1298–1307.
59. Luo H, Zou J, Dong Z, Zeng Q, Wu D, Liu L: Up-regulated miR-17 promotes
cell proliferation, tumour growth and cell cycle progression by targeting
the RND3 tumour suppressor gene in colorectal carcinoma. Biochem J
2012, 442:311–321.
60. Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, Yang S, Zhang S, Liu L, Lu M,
O'Connor-McCourt M, et al: A map of human cancer signaling. Mol Syst
Biol 2007, 3:152.
61. Cui Q, Yu Z, Purisima EO, Wang E: Principles of microRNA regulation of a
human cellular signaling network. Mol Syst Biol 2006, 2:46.
62. Yu W, Clyne M, Khoury MJ, Gwinn M: Phenopedia and Genopedia:
disease-centered and gene-centered views of the evolving knowledge
of human genetic associations. Bioinformatics 2010, 26:145–146. 64.
63. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R,
Leung K, Menzies A, et al: COSMIC: mining complete cancer genomes in
the Catalogue of Somatic Mutations in Cancer. Nucleic acids Res 2011,
39:D945–950.
64. Becker KG, Barnes KC, Bright TJ, Wang SA: The genetic association
database. Nat Genet 2004, 36:431–432.
65. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA: Online
Mendelian Inheritance in Man (OMIM), a knowledgebase of human
genes and genetic disorders. Nucleic acids Res 2005, 33:D514–517.
66. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M,
Marshall KA, Phillippy KH, Sherman PM, Holko M, et al: NCBI GEO: archive
for functional genomics data sets–update. Nucleic acids Res 2013,
41:D991–995.
67. Li J, Lenferink AE, Deng Y, Collins C, Cui Q, Purisima EO, O'Connor-McCourt MD,
Wang E: Identification of high-quality cancer prognostic markers and
metastasis network modules. Nat Commun 2010, 1:34.
68. Montgomery SB, Griffith OL, Sleumer MC, Bergman CM, Bilenky M,
Pleasance ED, Prychyna Y, Zhang X, Jones SJ: ORegAnno: an open access
database and curation system for literature-derived promoters, transcrip-
tion factor binding sites and regulatory variation. Bioinformatics 2006,
22:637–640.
69. Portales-Casamar E, Kirov S, Lim J, Lithwick S, Swanson MI, Ticoll A, Snoddy J,
Wasserman WW: PAZAR: a framework for collection and dissemination of
cis-regulatory sequence annotation. Genome Biol 2007, 8:R207.70. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K,
Karas D, Kel AE, Kel-Margoulis OV, et al: TRANSFAC: transcriptional regulation,
from patterns to profiles. Nucleic acids Res 2003, 31:374–378.
71. Zhao F, Xuan Z, Liu L, Zhang MQ: TRED: a Transcriptional Regulatory
Element Database and a platform for in silico gene regulation studies.
Nucleic acids Res 2005, 33:D103–107.
72. Dreszer TR, Karolchik D, Zweig AS, Hinrichs AS, Raney BJ, Kuhn RM, Meyer LR,
Wong M, Sloan CA, Rosenbloom KR, et al: The UCSC Genome Browser
database: extensions and updates 2011. Nucleic acids Res 2012, 40:D918–923.
73. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
Schwikowski B, Ideker T: Cytoscape: a software environment for
integrated models of biomolecular interaction networks. Genome Res
2003, 13:2498–2504.
74. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001,
98:5116–5121.
75. de Hoon MJ, Imoto S, Nolan J, Miyano S: Open source clustering software.
Bioinformatics 2004, 20:1453–1454.
76. Kozomara A, Griffiths-Jones S: miRBase: integrating microRNA annotation
and deep-sequencing data. Nucleic acids Res 2011, 39:D152–157.
77. Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J, Lopez R:
A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic acids
research 2010, 38:W695–699.
doi:10.1186/1752-0509-7-122
Cite this article as: Li et al.: Functional analysis of microRNA and
transcription factor synergistic regulatory network based on identifying
regulatory motifs in non-small cell lung cancer. BMC Systems Biology
2013 7:122.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
